<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005183A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005183</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13928696</doc-number><date>20130627</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>487</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>519</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>487</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>519</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>5142285</main-classification><further-classification>544117</further-classification><further-classification>5142342</further-classification><further-classification>544280</further-classification><further-classification>5142651</further-classification><further-classification>544 71</further-classification><further-classification>544230</further-classification><further-classification>544 61</further-classification><further-classification>5142332</further-classification><further-classification>544105</further-classification><further-classification>5142305</further-classification></classification-national><invention-title id="d0e43">Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61820828</doc-number><date>20130508</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61666299</doc-number><date>20120629</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="obligated-assignee"><addressbook><orgname>Pfizer Inc.</orgname><address><city>Groton</city><state>CT</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Galatsis</last-name><first-name>Paul</first-name><address><city>Newton</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Hayward</last-name><first-name>Matthew Merrill</first-name><address><city>Old Lyme</city><state>CT</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Kormos</last-name><first-name>Bethany Lyn</first-name><address><city>Somerville</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Wager</last-name><first-name>Travis T.</first-name><address><city>Brookline</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Zhang</last-name><first-name>Lei</first-name><address><city>Auburndale</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Stepan</last-name><first-name>Antonia Friederike</first-name><address><city>Providence</city><state>RI</state><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>Henderson</last-name><first-name>Jaclyn Louise</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>Kurumbail</last-name><first-name>Ravi G.</first-name><address><city>East Lyme</city><state>CT</state><country>US</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>Verhoest</last-name><first-name>Patrick Robert</first-name><address><city>Newton</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="25.74mm" wi="54.53mm" file="US20140005183A1-20140102-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0003" num="0000">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4 </sup>and R<sup>5 </sup>are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.</p></abstract></us-patent-application>